MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 9.9% from a year ago
Cash & equivalents stood at $298.49M at the end of Q1 FY2026, up 9.9% from a year earlier and down 10.8% from the prior quarter. Over 3 fiscal years it compounded at +103.8% a year.
Context
- Cash & equivalents amounted to 74.6% of total assets at the end of Q1 FY2026, up 21.4 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +9.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 334.52M USD
- Year-over-year change
- +85.4%
- 4-year CAGR
- +154.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 334.52M | +85.4% |
| FY2024 | 2024-12-31 | 180.43M | -60.0% |
| FY2023 | 2023-12-31 | 451.17M | +1042.0% |
| FY2022 | 2022-12-31 | 39.51M | +391.4% |
| FY2021 | 2021-12-31 | 8.04M | — |
Cash & Equivalents vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's Mar 2026 cash & equivalents of $298.49M is the 2nd highest of the 11 companies compared; the peer median is $87.13M.
- Its year-over-year change of +9.9% is the 7th highest of 10, against a peer median of +109.9%.
- Cash & equivalents amounts to 74.6% of total assets for MLTX, versus a peer median of 42.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $298.49M | +9.9% | +103.8% | 74.6% | |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $191.52M | +109.9% | +3.4% | 15.6% |
| Jun 2026 | $110.55M | +735.2% | +49.3% | 9.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $63.71M | -58.0% | +51.8% | 11.4% |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Dec 2025 | $38.35M | -51.0% | -21.4% | 68.4% | |
| Jun 2026 | $32.83M | — | — | 25.6% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Peer median (excluding MLTX) | $87.13M | +109.9% | +49.3% | 42.9% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.04M | 39.51M | 451.17M | 180.43M | 334.52M |
| Short-term Investments | 0 | 32.61M | 59.84M | 267.6M | 59.45M |
| Net Receivables | 148.77K | 217.13K | 1.06M | 2.84M | 4.87M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 9.64M | 76.51M | 514.17M | 474.29M | 421.69M |
| Property, Plant & Equipment (Net) | 45.74K | 331.97K | 3.95M | 3.64M | 2.14M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 115.04M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (115.04M) | (0) | 8.42M | 0 | 596K |
| Total Non-current Assets | 45.74K | 331.97K | 12.37M | 3.64M | 2.74M |
| Total Assets | 9.68M | 76.84M | 526.54M | 477.93M | 424.43M |
| Account Payables | 1.23M | 47.48K | 1.46M | 8.68M | 0 |
| Short-term Debt | 15M | 0 | 0 | 0 | 1.23M |
| Tax Payables | 63.92K | 109.83K | 367.98K | 642.11K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.3M | 109.83K | 2.78M | 4.24M | 40.83M |
| Total Current Liabilities | 21.09M | 7.67M | 9.97M | 22.46M | 45.48M |
| Long-term Debt | 0 | 0 | 0 | 0 | 74.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.86K | 282.21K | 583.43K | 620.68K | (374K) |
| Total Non-current Liabilities | 239.86K | 411.16K | 3.08M | 2.08M | 74.47M |
| Total Liabilities | 21.33M | 8.08M | 13.05M | 24.54M | 119.95M |
| Common Stock | 38.54K | 5.27K | 6.3K | 6.39K | 7K |
| Retained Earnings | (53.64M) | (80.65M) | (116.66M) | (235.59M) | (462.91M) |
| Accumulated OCI | (168.18K) | 350.95K | 2.36M | 5M | 604K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 19.87M | 17.82M | 6.57M | 0 |
| Total Equity | (11.65M) | 68.77M | 513.49M | 453.39M | 304.48M |
| Total Debt | 15M | 282.58K | 3.7M | 2.83M | 75.71M |
| Net Debt | 6.96M | (39.22M) | (447.47M) | (177.6M) | (258.81M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.